SGLT2 Dapagliflozin May Lower Heart Failure Risk in Genetic Carriers

SGLT2 Dapagliflozin May Lower Heart Failure Risk in Genetic Carriers
news.spreely.com

SGLT2 Dapagliflozin May Lower Heart Failure Risk in Genetic Carriers

The new analysis of dapagliflozin, a diabetes drug, suggests it may cut heart failure risk dramatically for people who carry rare genetic variants tied to cardiomyopathy, based on data from a large randomized trial. Researchers examined over 12,000 adults with type 2 diabetes and elevated cardiovascular risk, focusing on roughly 121 carriers of potentially harmful...